261 related articles for article (PubMed ID: 34762100)
21. Contemporary National Trends of Prostate Cancer Screening Among Privately Insured Men in the United States.
Kim SP; Karnes RJ; Gross CP; Meropol NJ; Van Houten H; Abouassaly R; Shah ND
Urology; 2016 Nov; 97():111-117. PubMed ID: 27527411
[TBL] [Abstract][Full Text] [Related]
22. Downstream tests, treatments, and annual direct payments in older men cared for by primary care providers with high or low prostate-specific antigen screening rates using 100 percent Texas U.S. Medicare public insurance claims data: a retrospective cohort study.
Zanwar P; Lin YL; Kuo YF; Goodwin JS
BMC Health Serv Res; 2016 Jan; 16():17. PubMed ID: 26772175
[TBL] [Abstract][Full Text] [Related]
23. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.
Martin RM; Donovan JL; Turner EL; Metcalfe C; Young GJ; Walsh EI; Lane JA; Noble S; Oliver SE; Evans S; Sterne JAC; Holding P; Ben-Shlomo Y; Brindle P; Williams NJ; Hill EM; Ng SY; Toole J; Tazewell MK; Hughes LJ; Davies CF; Thorn JC; Down E; Davey Smith G; Neal DE; Hamdy FC;
JAMA; 2018 Mar; 319(9):883-895. PubMed ID: 29509864
[TBL] [Abstract][Full Text] [Related]
24. Disparities Associated with Shared Decision-making in Prostate Cancer Screening.
Basin MF; Crane K; Basnet A; Chandrasekar T; Shapiro O; Jacob JM; Bratslavsky G; Goldberg H
Eur Urol Focus; 2023 Nov; 9(6):1008-1015. PubMed ID: 37198068
[TBL] [Abstract][Full Text] [Related]
25. Low-Value Prostate-Specific Antigen Screening in Older Males.
Kalavacherla S; Riviere P; Javier-DesLoges J; Banegas MP; McKay RR; Murphy JD; Rose BS
JAMA Netw Open; 2023 Apr; 6(4):e237504. PubMed ID: 37040113
[TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen testing: men's responses to 2012 recommendation against screening.
Squiers LB; Bann CM; Dolina SE; Tzeng J; McCormack L; Kamerow D
Am J Prev Med; 2013 Aug; 45(2):182-9. PubMed ID: 23867025
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of Screening for Prostate Cancer Among Men Who Use Statins.
Vettenranta A; Murtola TJ; Raitanen J; Raittinen P; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
JAMA Oncol; 2022 Jan; 8(1):61-68. PubMed ID: 34817559
[TBL] [Abstract][Full Text] [Related]
28. Screening: Actual trends on PSA marker. When, who, how?
Baccaglini W; Cathelineau X; Araújo Glina FP; Medina LG; Sotelo R; Carneiro A; Sanchez-Salas R
Arch Esp Urol; 2019 Mar; 72(2):98-103. PubMed ID: 30855010
[TBL] [Abstract][Full Text] [Related]
29. Decrease in Prostate Cancer Testing Following the US Preventive Services Task Force (USPSTF) Recommendations.
Li J; Berkowitz Z; Hall IJ
J Am Board Fam Med; 2015; 28(4):491-3. PubMed ID: 26152440
[TBL] [Abstract][Full Text] [Related]
30. Impact of the 2008 U.S. Preventative Services Task Force recommendation on frequency of prostate-specific antigen screening in older men.
Lee SY; Friderici J; Stefan MS; Rothberg MB
J Am Geriatr Soc; 2014 Oct; 62(10):1912-5. PubMed ID: 25284269
[TBL] [Abstract][Full Text] [Related]
31. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.
Moyer VA;
Ann Intern Med; 2012 Jul; 157(2):120-34. PubMed ID: 22801674
[TBL] [Abstract][Full Text] [Related]
32. The Association of Veterans' PSA Screening Rates With Changes in USPSTF Recommendations.
Becker DJ; Rude T; Walter D; Wang C; Loeb S; Li H; Ciprut S; Kelly M; Zeliadt SB; Fagerlin A; Lepor H; Sherman S; Ravenell JE; Makarov DV
J Natl Cancer Inst; 2021 May; 113(5):626-631. PubMed ID: 32797212
[TBL] [Abstract][Full Text] [Related]
33. Is anyone listening? Variation in PSA screening among providers for men 75+ before and after United States Preventive Services Task Force recommendations against it: a retrospective cohort study.
Goodwin JS; Jaramillo E; Yang L; Kuo YF; Tan A
PLoS One; 2014; 9(9):e107352. PubMed ID: 25208250
[TBL] [Abstract][Full Text] [Related]
34. Low-Value Prostate-Specific Antigen Test for Prostate Cancer Screening and Subsequent Health Care Utilization and Spending.
Kim DD; Daly AT; Koethe BC; Fendrick AM; Ollendorf DA; Wong JB; Neumann PJ
JAMA Netw Open; 2022 Nov; 5(11):e2243449. PubMed ID: 36413364
[TBL] [Abstract][Full Text] [Related]
35. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.
Perez TY; Danzig MR; Ghandour RA; Badani KK; Benson MC; McKiernan JM
Urology; 2015 Jan; 85(1):85-9. PubMed ID: 25440819
[TBL] [Abstract][Full Text] [Related]
36. The current state of prostate-specific antigen testing.
Lewis R; Hornberger B
JAAPA; 2016 Sep; 29(9):51-3. PubMed ID: 27575906
[TBL] [Abstract][Full Text] [Related]
37. Time trends in prostate cancer screening in Swiss primary care (2010 to 2017) - A retrospective study.
Zechmann S; Di Gangi S; Kaplan V; Meier R; Rosemann T; Valeri F; Senn O;
PLoS One; 2019; 14(6):e0217879. PubMed ID: 31194773
[TBL] [Abstract][Full Text] [Related]
38. Changing clinical trends in 10 000 robot-assisted laparoscopic prostatectomy patients and impact of the 2012 US Preventive Services Task Force's statement against PSA screening.
Onol FF; P Ganapathi H; Rogers T; Palmer K; Coughlin G; Samavedi S; Coelho R; Jenson C; Sandri M; Rocco B; Patel V
BJU Int; 2019 Dec; 124(6):1014-1021. PubMed ID: 31301265
[TBL] [Abstract][Full Text] [Related]
39. Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening.
Zakaria AS; Dragomir A; Brimo F; Kassouf W; Tanguay S; Aprikian A
BMC Urol; 2018 Aug; 18(1):69. PubMed ID: 30126402
[TBL] [Abstract][Full Text] [Related]
40. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.
Fleshner K; Carlsson SV; Roobol MJ
Nat Rev Urol; 2017 Jan; 14(1):26-37. PubMed ID: 27995937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
